Literature DB >> 31819009

PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.

Nicholas E Powers1, Benjamin Swartzwelter2, Carlo Marchetti2, Dennis M de Graaf2,3, Alexandra Lerchner4, Martin Schlapschy5, Rajiv Datar6, Uli Binder4, Carl K Edwards6, Arne Skerra5, Charles A Dinarello2,3.   

Abstract

Interleukin-1 (IL-1) is a key mediator of inflammation and immunity. Naturally-occurring IL-1 receptor antagonist (IL-1Ra) binds and blocks the IL-1 receptor-1 (IL-1R1), preventing signaling. Anakinra, a recombinant form of IL-1Ra, is used to treat a spectrum of inflammatory diseases. However, anakinra is rapidly cleared from the body and requires daily administration. To create a longer-lasting alternative, PASylated IL-1Ra (PAS-IL-1Ra) has been generated by in-frame fusion of a long, defined-length, N-terminal Pro/Ala/Ser (PAS) random-coil polypeptide with IL-1Ra. Here, we compared the efficacy of two PAS-IL-1Ra molecules, PAS600-IL-1Ra and PAS800-IL-1Ra (carrying 600 and 800 PAS residues, respectively), with that of anakinra in mice. PAS600-IL-1Ra displayed markedly extended blood plasma levels 3 days post-administration, whereas anakinra was undetectable after 24 h. We also studied PAS600-IL-1Ra and PAS800-IL-1Ra for efficacy in monosodium urate (MSU) crystal-induced peritonitis. 5 days post-administration, PAS800-IL-1Ra significantly reduced leukocyte influx and inflammatory markers in MSU-induced peritonitis, whereas equimolar anakinra administered 24 h before MSU challenge was ineffective. The 6-h pretreatment with equimolar anakinra or PAS800-IL-1Ra before MSU challenge similarly reduced inflammatory markers. In cultured A549 lung carcinoma cells, anakinra, PAS600-IL-1Ra, and PAS800-IL-Ra reduced IL-1α-induced IL-6 and IL-8 levels with comparable potency. In human peripheral blood mononuclear cells, these molecules suppressed Candida albicans-induced production of the cancer-promoting cytokine IL-22. Surface plasmon resonance analyses revealed significant binding between PAS-IL-1Ra and IL-1R1, although with a slightly lower affinity than anakinra. These results validate PAS-IL-1Ra as an active IL-1 antagonist with marked in vivo potency and a significantly extended half-life compared with anakinra.
© 2020 Powers et al.

Entities:  

Keywords:  IL-22; PASylation; biotechnology; drug delivery; half-life extension; inflammation; innate immunity; interleukin 1 (IL-1); intrinsically-disordered protein; leukocyte; pharmacokinetics

Mesh:

Substances:

Year:  2019        PMID: 31819009      PMCID: PMC6970921          DOI: 10.1074/jbc.RA119.010340

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

1.  IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation.

Authors:  Peleg Rider; Yaron Carmi; Ofer Guttman; Alex Braiman; Idan Cohen; Elena Voronov; Malka R White; Charles A Dinarello; Ron N Apte
Journal:  J Immunol       Date:  2011-09-19       Impact factor: 5.422

Review 2.  Structure-immunogenicity relationships of therapeutic proteins.

Authors:  Suzanne Hermeling; Daan J A Crommelin; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2004-06       Impact factor: 4.200

3.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

Review 4.  Patient adherence to treatment: three decades of research. A comprehensive review.

Authors:  E Vermeire; H Hearnshaw; P Van Royen; J Denekens
Journal:  J Clin Pharm Ther       Date:  2001-10       Impact factor: 2.512

Review 5.  Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity.

Authors:  Alberto Mantovani; Charles A Dinarello; Martina Molgora; Cecilia Garlanda
Journal:  Immunity       Date:  2019-04-16       Impact factor: 31.745

6.  Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs.

Authors:  Lucy J Holt; Amrik Basran; Kate Jones; Jennifer Chorlton; Laurent S Jespers; Neil D Brewis; Ian M Tomlinson
Journal:  Protein Eng Des Sel       Date:  2008-04-02       Impact factor: 1.650

7.  Targeting interleukin-22 for cancer therapy.

Authors:  Anamarija Markota; Stefan Endres; Sebastian Kobold
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

8.  Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action.

Authors:  Michaela Gebauer; Arne Skerra
Journal:  Bioorg Med Chem       Date:  2017-09-15       Impact factor: 3.641

9.  High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins.

Authors:  Daniel G Rudmann; James T Alston; Jeffrey C Hanson; Shawn Heidel
Journal:  Toxicol Pathol       Date:  2013-06-20       Impact factor: 1.902

10.  Corrigendum: Anakinra Therapy for Non-cancer Inflammatory Diseases.

Authors:  Giulio Cavalli; Charles A Dinarello
Journal:  Front Pharmacol       Date:  2019-03-08       Impact factor: 5.810

View more
  4 in total

1.  Targeting Tumor-Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer.

Authors:  Austin R Dosch; Samara Singh; Xizi Dai; Siddharth Mehra; Iago De Castro Silva; Anna Bianchi; Supriya Srinivasan; Zhen Gao; Yuguang Ban; Xi Chen; Sulagna Banerjee; Nagaraj S Nagathihalli; Jashodeep Datta; Nipun B Merchant
Journal:  Mol Cancer Ther       Date:  2021-09-13       Impact factor: 6.261

2.  A genome-engineered bioartificial implant for autoregulated anticytokine drug delivery.

Authors:  Yun-Rak Choi; Kelsey H Collins; Luke E Springer; Lara Pferdehirt; Alison K Ross; Chia-Lung Wu; Franklin T Moutos; Natalia S Harasymowicz; Jonathan M Brunger; Christine T N Pham; Farshid Guilak
Journal:  Sci Adv       Date:  2021-09-01       Impact factor: 14.136

3.  IL‑1β‑induced pentraxin 3 inhibits the proliferation, invasion and cell cycle of trophoblasts in preeclampsia and is suppressed by IL‑1β antagonists.

Authors:  Xiaoxi Wang; Jing Zhang; Jing Ji
Journal:  Mol Med Rep       Date:  2022-02-09       Impact factor: 2.952

4.  Direct Affinity Purification of Long-Acting PASylated Proteins with Therapeutic Potential Using L-Prolinamide for Mild Elution.

Authors:  Jonas Schilz; Charlotte Clement; Franziska Greiner; Arne Skerra
Journal:  Angew Chem Int Ed Engl       Date:  2022-04-27       Impact factor: 16.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.